Table 2.

Pharmacokinetic parameters after single oral or intravenous administration of unlabeled amenamevir or ¹⁴C-amenamevir to mice

Dose (mg/kg) and dosing route	Matrix	Analyte	C max (ng/mL)	T max (h)	CLtotal (L/h/kg)	Vdss (L/kg)	AUCinf (μg × h/mL)	F or Fa (%)
1a, po	Plasma	Amenamevir	72	1.0	N.A.	N.A.	0.35	40.5e
3a, po	Plasma	Amenamevir	265	1.0	N.A.	N.A.	1.05	40.5e
10a, po	Plasma	Amenamevir	893	1.0	N.A.	N.A.	3.97	46.1e
3a, iv	Plasma	Amenamevir	N.A.	N.A.	1.16	3.14	2.59	N.A.
3b, po	Plasma	Radioactivity	429c	1.0	N.A.	N.A.	1.82d	40.1f
3b, iv	Plasma	Radioactivity	N.A.	N.A.	N.A.	N.A.	4.55d	N.A.
3b, po	Blood	Radioactivity	363c	1.0	N.A.	N.A.	1.61d	38.8f
3b, iv	Blood	Radioactivity	N.A.	N.A.	N.A.	N.A.	4.14d	N.A.

Each parameter was calculated from the mean concentration–time profile of three animals

N.A. Not applicable, iv intravenous, po oral, C_max maximum concentration, T_max time to reach C_max, CL_Total apparent toal clearance, Vd_ss volume of distribution at steady state, AUC_inf area under the concentration-time curve from time 0 to infinity, F absoute bioavailability, F_a absorption ratio 

^aUnlabeled amenamevir was administered, ^{b 14}C-amenamevir was administered, ^cng eq./mL, ^dμg eq. × h/mL, ^eF, ^fFa